BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 27612492)

  • 21. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benralizumab: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):505-511. PubMed ID: 29464664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 29. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
    Bourdin A; Shaw D; Menzies-Gow A; FitzGerald JM; Bleecker ER; Busse WW; Ferguson GT; Brooks L; Barker P; Gil EG; Martin UJ
    J Asthma; 2021 Apr; 58(4):514-522. PubMed ID: 31859541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
    J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
    Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.
    Chupp G; Lugogo NL; Kline JN; Ferguson GT; Hirsch I; Goldman M; Zangrilli JG; Trudo F
    Ann Allergy Asthma Immunol; 2019 May; 122(5):478-485. PubMed ID: 30802500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
    Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
    Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
    Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
    Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.